501-3292
Production Way, Burnaby, B.C., V5A 4R4
Phone:
(604) 551-7831 Fax:
604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com
Cannabix
Technologies Granted
U.
S. Patent for FAIMS molecular analysis device
Cannabix
is developing
Marijuana
Breathalyzer
devices to
give law enforcement and employers
a
tool to
enhance
public safety
Vancouver, British
Columbia -- August
17, 2021
--
InvestorsHub NewsWire -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the "Company" or
"Cannabix")
developer
of the Cannabix Marijuana Breathalyzer devices
for law
enforcement and the workplace, is pleased to
report that the United
States Patent and
Trademark Office (USPTO) has granted
patent
No. 17/019728
entitled,
"Apparatus and Methods
for Detection of Molecules" to the
Company. This
patent
is
centered on innovations
made by
Cannabix with its
FAIMS
(field
asymmetric waveform ion mobility spectrometry)
based
marijuana
breathalyzer technology. This patent is the culmination of research
and development work conducted by Cannabix scientists and engineers
in the areas of ion mobility spectrometry, non-volatile molecule
sampling and fluid
dynamics. These
developments
provide
utility in several
areas
related to detection of target
molecules
in breath.
The Company is
developing a FAIMS based drug screening
device that would be used by law enforcement, laboratories and
other end users to detect cannabis in exhaled
breath.
Cannabix
is using its FAIMS technology to detect ?9-tetrahydrocannabinol
("THC"),
a non-volatile compound, in breath. The Cannabix FAIMS marijuana
breathalyzer device uses ion mobility filtering techniques related
to mass spectrometry – the gold standard analytical technique for
molecular detection. The Cannabix device
has been designed and built in a series of modules that together
allow for sample intake, ionization, filtering and detection
at
atmospheric
pressure. In addition, the
device has the ability to couple directly
to a mass
spectrometer for validation with
gold standard techniques. In conjunction with
the accomplishments described in the granted patent,
engineers have been
improving
efficiencies in the electronics, sample intake and
portability.
The Company has been
steadily growing its intellectual property (IP) portfolio over
recent months. In June, the Company was granted patent
No.
2887841 entitled, "Cannabis Drug Detection Device" from
the
Canadian
Intellectual Property Office.
In
January, the USPTO granted a granted patent No.
14/689434 entitled, "Cannabis Drug Detection Device"
to the
Company. This newly granted patent from the USPTO
for FAIMS
and the detection of molecules is a welcome addition to the
Company's IP development efforts.
About Cannabix
Technologies Inc.
Cannabix Technologies
Inc. is a developer of marijuana breathalyzer technologies for law
enforcement and the workplace. Cannabix is working to develop
drug-screening devices that will detect THC - the
psychoactive component of
marijuana that causes impairment using breath samples. Breath
testing for THC would allow employers and law
enforcement to identify
recent marijuana use that better
aligns with impairment.
We seek Safe
Harbor.
On
behalf of the Board of Directors
"Rav
Mlait"
CEO
Cannabix Technologies
Inc.
For
further information, contact the Company at
info@cannabixtechnologies.com
The
CSE has not reviewed and does not accept responsibility for the
adequacy or accuracy of this release.
Cautionary Statement
Regarding Forward-Looking Statements
This press release
contains forward-looking information that involves various risks
and uncertainties regarding future events. Such forward-looking
information can include without limitation statements based on
current expectations involving a number of risks and uncertainties
and are not guarantees of future performance of the Company, such
as final development of a commercial or prototype product(s),
successful trial or pilot of company technologies, no assurance
that commercial sales of any kind actually materialize; no
assurance the Company will have sufficient funds to complete
product development. There are numerous risks and uncertainties
that could cause actual results and the Company's plans and
objectives to differ materially from those expressed in the
forward-looking information, including: (i) adverse market
conditions; (ii) risks regarding protection of proprietary
technology; (iii) the ability of the Company to complete
financings; (iv) the ability of the Company to develop and market
its future product; and (v) risks regarding government regulation,
managing and maintaining growth, the effect of adverse publicity,
litigation, competition and other factors which may be identified
from time to time in the Company's public announcements and
filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built or proceed. There is
no assurance that existing "patent pending" technologies licensed
by the Company will receive patent status by regulatory
authorities. The Company is not currently selling commercial
breathalyzers. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.